MagVenture, Inc.: Robotic Aid to Drugfree Depression Treatment Receives FDA Clearance
ALPHARETTA, Georgia, Feb. 20, 2019 -- (Healthcare Sales &Marketing Network) -- MagVenture, a medical device company providing drugfree depression treatment to the US since 2015, has added a new, FDA cleared robotic platform to their clinical system. This... Devices, Neurology, FDA MagVenture, TMS-Cobot, neuromodulation, Transcranial Magnetic Stimulation
CrystEngComm, 2019, Accepted Manuscript DOI: 10.1039/C8CE02076K, PaperPaulo de Sousa de Sousa Carvalho, Jr., Luan Farinelli Diniz, Juan Carlos Tenorio Clavijo, Matheus S. Souza, Chris Hebert Jesus Franco, Rafael C. Rial, Karla Regina Warszawski, Carlos E. D. Nazario, Javier A Ellena Paroxetine hydrochloride, PRX HCl, is an important and widely prescribed antidepressant drug for anxiety and depression treatment. Since hydrochloride salt can imply problems in its manufacture, we have designed organic... The content of this RSS Feed (c) The Royal Society of Chemistry
Conclusion: few studies compared the relationship between the variables among the elderly. A probable association between the variables for both genders has been found, suggesting that the advancing age contributes to the increase of tinnitus severity and its psychological symptoms, affecting the quality of life of these individuals. Further studies are suggested to confirm the association between tinnitus, anxiety and depression in the elderly. Multi-professional work is important for the evaluation and treatment of these people.RESUMO Objetivo: verificar na literatura uma prov ável associação do zumb...
Publication date: Available online 24 March 2019Source: Social Science &MedicineAuthor(s): Mirkka Danielsbacka, Antti O. Tanskanen, David A. Coall, Markus JokelaAbstractPrevious studies suggest grandparental childcare is associated with improved health and well-being of grandparents but limited information on the causal nature of this association exists. Here, we use the longitudinal Survey of Health, Ageing and Retirement in Europe (SHARE) of people aged 50 and above across 11 countries including follow-up waves between 2004 and 2015 (n = 41,713 person-observations from 24,787 unique persons of whom 11,102 had two...
Nexstim said today that it won FDA 510(k) clearance for a new, shorter treatment protocol for its Navigated Brain Therapy transcranial magnetic stimulation system intended to treat major depressive disorder. The Helsinki-based company said that the FDA cleared the system for a Theta Burst Stimulation treatment protocol, which is much shorter than its previously cleared treatment protocol. The newly cleared protocol for the NBT system takes only 3 minutes per session, significantly shorter than the 37-minute standard treatment protocol the company won FDA clearance for in November 2017. Nexstim said that a large multi-cente...
Condition: Depression Intervention: Behavioral: Depression Medication Choice Sponsors: Laval University; Réseau-1 Québec; CERSSPL Not yet recruiting
Conditions: Unspecified Child Maltreatment, Suspected; Unspecified Child Maltreatment, Confirmed; Postpartum Depression Interventions: Other: Enhanced Intervention; Other: Intervention Sponsor: Northwell Health Enrolling by invitation
Condition: Treatment Resistant Depression Intervention: Device: Vagal Nerve Stimulation (VNS) Sponsor: LivaNova Not yet recruiting
Condition: Depressive Disorder, Treatment-Resistant Interventions: Drug: Ethosuximide; Drug: Placebo; Drug: Escitalopram Sponsor: Zhejiang University Not yet recruiting
A brain imaging study identified ties between childhood maltreatment, brain structural alterations, and vulnerability to recurrent depression.Medscape Medical News
(MedPage Today) -- Health news and commentary from around the Web gathered by the MedPage Today staff